Sector News

GSK and IDEAYA partner in synthetic lethality

June 18, 2020
Life sciences

GlaxoSmithKline and IDEAYA Biosciences have announced a strategic partnership in synthetic lethality, an emerging arm of oncology and a core research focus for GSK.

In synthetic lethality, cells can cope with the loss of single genes in isolation but a combination of deficiencies in two or more genes leads to cell death. When tumour suppressor genes are functionally lost in cancer, this mode of action can be used to exploit tumour-specific vulnerabilities through new medicines for patients with cancer.

The partnership includes IDEAYA’s synthetic lethality programs MAT2A, Pol Theta, and Werner Helicase programmes, which should reach clinical trials within the next three years.

IDEAYA has solved the crystal structures for each these programmes, facilitating structure-based drug design, and has demonstrated in vivo proof of concept in relevant animal models for its MAT2A and Pol Theta programmes.

“GSK is the ideal strategic partner for IDEAYA, as this partnership enables compelling potential combinations and the opportunity to build the industry leading synthetic lethality pipeline that targets molecularly defined populations in several major solid tumours, including potentially lung, prostate, breast, colorectal, and ovarian cancer,” said Yujiro S. Hata, the firm’s chief executive and president.

Under the terms of the partnership, IDEAYA will lead the MAT2A programme through early clinical development and is responsible for all costs prior to the GSK option exercise, after which it is responsible for 20% of global development costs.

In return, IDEAYA will receive a 50% US profit share and ex-US royalties for the MAT2A and Werner Helicase programmes and is responsible for 20% of global development costs for licensed products being developed with GSK.

The group also stands to bank global royalties for the Pol Theta programme, and GSK will cover all research, development, and commercialisation costs.

GSK is responsible for all commercialisation activities and costs globally for licensed products.

By: Selina McKee

Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).